In May of 2025, Colibri Heart Valve LLC (“Colibri”) sued Medtronic CoreValve, LLC (“Medtronic”) for infringement of U.S. Patent No. 8,900,294, (the “’294 patent”). The ’294 patent is directed to a ...
Medtronic wins US appeal to overturn $106.5 mln heart-valve patent verdict A U.S. appeals court on Friday overturned a jury's verdict that medical device maker Medtronic owes competitor Colibri $106.5 ...
Medtronic reported late-breaking data on five-year outcomes from the Evolut Low Risk Trial. The Dublin-based company said data shows, vs. surgery, the Evolut transcatheter aortic valve replacement ...
Surgical aortic valve replacement (SAVR) devices are widely believed to be considerably more durable than transcatheter aortic valve replacement (TAVR) devices, but five-year data for Medtronic plc’s ...
A federal jury in California said Wednesday that a unit of Medtronic must pay $106.5 million to competitor Colibri Heart Valve LLC for patent infringement. After a seven-day trial in Santa Ana, Calif.
Please provide your email address to receive an email when new articles are posted on . Transcatheter aortic valve replacement using a self-expanding bioprosthesis was associated with lower risk for ...
Please provide your email address to receive an email when new articles are posted on . Pooled data from two registries have confirmed a previous report that a next-generation transcatheter aortic ...
Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the National Medical Products Administration (NMPA) has approved the CoreValve™ Evolut™ PRO TAVR system for the ...
In a randomized clinical trial, SCOPE II, a new self-expanding bioprosthetic valve used in transcatheter aortic valve replacement (TAVR) failed to demonstrate non-inferiority compared to an existing ...
In a randomized clinical trial, SCOPE II, a new self-expanding bioprosthetic valve used in transcatheter aortic valve replacement (TAVR) failed to demonstrate non-inferiority compared to an existing ...
In a head-to-head study of two supra-annular, self-expanding TAVR devices, CoreValve Evolut (Medtronic) appears to be a better option than the Acurate neo valve (Boston Scientific) for the treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results